CMV esophagitis: Difference between revisions

No edit summary
 
Line 1: Line 1:
==Background==
==Background==
*Cytomegalovirus (CMV) gastrointestinal disease is an uncommon but serious complication of [[AIDS]].
*[[Cytomegalovirus]] (CMV) gastrointestinal disease is an uncommon but serious complication of [[AIDS]].
*The diagnosis of CMV gastrointestinal disease should be suspected in patients with CD4 cell counts <50 cells/microL who present with symptoms of esophagitis, gastritis, enteritis, or colitis.
*The diagnosis of CMV gastrointestinal disease should be suspected in patients with CD4 cell counts <50 cells/microL who present with symptoms of esophagitis, gastritis, enteritis, or colitis.
*The incidence of CMV gastrointestinal disease has decreased substantially since antiretroviral therapy (ART) became available  
*The incidence of CMV gastrointestinal disease has decreased substantially since antiretroviral therapy (ART) became available  
Line 9: Line 9:
*[[Fever]]
*[[Fever]]
*[[Nausea]]
*[[Nausea]]
*Substernal burning pain
*[[chest pain|Substernal]] burning pain


==Differential Diagnosis==
==Differential Diagnosis==
Line 27: Line 27:


==Disposition==
==Disposition==
===Antivirals===
{{CMV esophagitis treatment}}


==See Also==
==See Also==

Latest revision as of 20:06, 29 September 2019

Background

  • Cytomegalovirus (CMV) gastrointestinal disease is an uncommon but serious complication of AIDS.
  • The diagnosis of CMV gastrointestinal disease should be suspected in patients with CD4 cell counts <50 cells/microL who present with symptoms of esophagitis, gastritis, enteritis, or colitis.
  • The incidence of CMV gastrointestinal disease has decreased substantially since antiretroviral therapy (ART) became available

Clinical Features

Differential Diagnosis

Esophagitis Types

CMV Diseases

Evaluation

Management

    • Ganciclovir: 5mg/kg/dose IV q12h
    • Foscarnet: 60mg/kg/dose q8h or 90mg/kg/dose q12h
    • Valganciclovir: 900mg PO twice daily
      • May be used for induction therapy, in place of intravenous ganciclovir, in patients who can tolerate and absorb oral medications
    • The recommended duration of therapy for CMV gastrointestinal disease in patients with AIDS is 3-6 weeks
    • Chronic maintenance therapy is not recommended for CMV gastrointestinal disease unless there is concurrent retinitis or recurrent gastrointestinal disease after induction therapy has been discontinued.

Disposition

See Also

External Links

References